Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$17.40 USD
-0.07 (-0.40%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $17.40 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
A Value D Growth B Momentum C VGM
Company Summary
Headquartered in Plainsboro, NJ, Integra LifeSciences is one of the world leaders in regenerative medicine. The company develops, manufactures and markets cost-effective surgical implants and medical instruments. The company now manufactures and sells products in the following two global reportable business segments: Codman Specialty Surgical (CSS) and Orthopedics and Tissue Technologies (OTT).
The CSS business (accounting for 68.7% of revenues in 2023, a rise of 3.9% from 2022), previously known as Specialty Surgical Solutions, offers global, market-leading technologies, brands and instrumentation. The acquisition of Codman Neurosurgery from Johnson & Johnson increased ...
Company Summary
Headquartered in Plainsboro, NJ, Integra LifeSciences is one of the world leaders in regenerative medicine. The company develops, manufactures and markets cost-effective surgical implants and medical instruments. The company now manufactures and sells products in the following two global reportable business segments: Codman Specialty Surgical (CSS) and Orthopedics and Tissue Technologies (OTT).
The CSS business (accounting for 68.7% of revenues in 2023, a rise of 3.9% from 2022), previously known as Specialty Surgical Solutions, offers global, market-leading technologies, brands and instrumentation. The acquisition of Codman Neurosurgery from Johnson & Johnson increased the global direct sales representation and international presence.
The global commercial network includes clinical specialists, a large direct global sales force and strategic partnerships and distributors that serve hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers and health care providers in North America, South America, Europe, Asia Pacific, Middle East and Africa.
The Tissue Technologies segment (31.3%, down 10.3%), includes wound reconstruction and repair products, bone grafts and nerve and tendon repair products. The company sold its Extremity Orthopedics business to Smith & Nephew. After selling this non-profitable business in January 2021, the company rebranded the Orthopedics and Tissue Technologies segment as Tissue Technologies in the first quarter of 2021.
The acquisition of Derma Sciences in 2017 provides the company with a relevant scale in outpatient wound care, doubling the sales force in the United States and broadening its business base with advanced products such as Medihoney, weight offloading and amniotic tissue. It also creates opportunities to further expand its footprint in the plastic and reconstructive surgery.
General Information
Integra LifeSciences Holdings Corporation
1100 CAMPUS ROAD
PRINCETON, NJ 08540
Phone: 609-275-0500
Fax: 609-750-4277
Web: http://www.integralife.com
Email: chris.ward@integralife.com
Industry | Medical - Instruments |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 10/23/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.39 |
Current Year EPS Consensus Estimate | 2.45 |
Estimated Long-Term EPS Growth Rate | 12.00 |
Exp Earnings Date | 10/23/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 17.47 |
52 Week High | 45.42 |
52 Week Low | 16.96 |
Beta | 1.10 |
20 Day Moving Average | 942,895.12 |
Target Price Consensus | 27.70 |
4 Week | -17.42 |
12 Week | -40.29 |
YTD | -60.05 |
4 Week | -18.40 |
12 Week | -42.82 |
YTD | -66.58 |
Shares Outstanding (millions) | 77.58 |
Market Capitalization (millions) | 1,349.93 |
Short Ratio | NA |
Last Split Date | 1/4/2017 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 7.09 |
Trailing 12 Months | 6.15 |
PEG Ratio | 0.59 |
vs. Previous Year | -11.27% |
vs. Previous Quarter | 14.55% |
vs. Previous Year | 9.68% |
vs. Previous Quarter | 13.37% |
Price/Book | 0.88 |
Price/Cash Flow | 3.60 |
Price / Sales | 0.86 |
6/30/24 | 14.07 |
3/31/24 | 14.27 |
12/31/23 | 15.19 |
6/30/24 | 5.66 |
3/31/24 | 5.98 |
12/31/23 | 6.59 |
6/30/24 | 3.39 |
3/31/24 | 4.68 |
12/31/23 | 3.45 |
6/30/24 | 2.10 |
3/31/24 | 3.35 |
12/31/23 | 2.18 |
6/30/24 | 14.15 |
3/31/24 | 15.04 |
12/31/23 | 16.07 |
6/30/24 | 1.51 |
3/31/24 | 2.63 |
12/31/23 | 4.39 |
6/30/24 | 1.73 |
3/31/24 | 3.01 |
12/31/23 | 5.26 |
6/30/24 | 19.77 |
3/31/24 | 20.33 |
12/31/23 | 20.31 |
6/30/24 | 1.74 |
3/31/24 | 1.77 |
12/31/23 | 1.80 |
6/30/24 | 1.17 |
3/31/24 | 1.15 |
12/31/23 | 0.94 |
6/30/24 | 54.00 |
3/31/24 | 53.47 |
12/31/23 | 48.33 |